NRx Pharmaceuticals (NASDAQ:NRXP) Given New $10.00 Price Target at BTIG Research

NRx Pharmaceuticals (NASDAQ:NRXP) had its price objective cut by BTIG Research to $10.00 in a report published on Friday morning,Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts also recently issued reports on NRXP. Wall Street Zen upgraded NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, June 14th. HC Wainwright restated a “buy” rating and set a $45.00 price objective on shares of NRx Pharmaceuticals in a research note on Monday, April 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NRx Pharmaceuticals in a research report on Wednesday. D. Boral Capital reiterated a “buy” rating and issued a $34.00 target price on shares of NRx Pharmaceuticals in a research note on Tuesday, May 5th. Finally, Ascendiant Capital Markets boosted their target price on shares of NRx Pharmaceuticals from $48.00 to $49.00 and gave the stock a “buy” rating in a report on Monday, April 27th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $34.50.

NRx Pharmaceuticals Stock Performance

NASDAQ NRXP opened at $3.58 on Friday. The firm’s 50 day moving average price is $3.90 and its 200-day moving average price is $2.92. NRx Pharmaceuticals has a 52-week low of $1.62 and a 52-week high of $5.05. The company has a market cap of $129.70 million, a PE ratio of -3.28 and a beta of 2.18.

NRx Pharmaceuticals (NASDAQ:NRXP) last issued its quarterly earnings data on Friday, May 15th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.01. The business had revenue of $1.07 million during the quarter, compared to the consensus estimate of $19.43 million. On average, analysts forecast that NRx Pharmaceuticals will post -0.3 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

A number of institutional investors have recently made changes to their positions in NRXP. Ethos Financial Group LLC grew its stake in NRx Pharmaceuticals by 33.6% during the 1st quarter. Ethos Financial Group LLC now owns 15,900 shares of the company’s stock worth $34,000 after buying an additional 4,000 shares during the last quarter. Global Retirement Partners LLC acquired a new position in NRx Pharmaceuticals during the 4th quarter valued at about $107,000. Two Sigma Investments LP raised its stake in NRx Pharmaceuticals by 66.4% in the third quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock valued at $173,000 after buying an additional 20,880 shares during the last quarter. State Street Corp raised its stake in NRx Pharmaceuticals by 14.0% in the fourth quarter. State Street Corp now owns 86,984 shares of the company’s stock valued at $236,000 after buying an additional 10,700 shares during the last quarter. Finally, Bleakley Financial Group LLC acquired a new stake in NRx Pharmaceuticals in the fourth quarter worth about $318,000. Institutional investors and hedge funds own 4.27% of the company’s stock.

NRx Pharmaceuticals Company Profile

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.